ClinicalTrials.gg
RecruitingNCT07071103ILDR-02Updated Nov 20, 2025

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

A Phase 2 interventional study of Low-dose radiotherapy to the intestine (ILDR) and PD-1/PD-L1 monoclonal antibodies in Radiotherapy, Metastatic Solid Cancers and Immune Checkpoint Blockade, sponsored by Chuangzhen Chen. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Chuangzhen Chen · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
272nd of 394
48 · median 80
Started
2025
with 55 others
Phase 2
146 of 502
72 open now
Primary completion
2028-01
later than 201 of 237 live
Registered
445th of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 272nd largest by planned enrollment of the 394 interventional ones that give a count, is one of 56 that started in 2025, is one of 146 in phase 2, reaches primary completion later than 201 of the 237 other live ones, and was the 445th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

205 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Preclinical and clinical evidence suggests that intestinal low-dose radiotherapy (ILDR) may enhance antitumor immune responses by modulating the gut microenvironment, thereby improving the efficacy of immune checkpoint inhibitors (ICBs) in refractory solid tumors. Based on these findings, the investigators initiate a multicohort phase II clinical trial to evaluate the clinical benefit and safety of ILDR combined with PD-1/PD-L1 monoclonal antibody therapy in patients with metastatic solid tumors resistant to prior ICB treatment.

In this study, patients are stratified into three parallel cohorts by tumor type (lung cancer, esophageal cancer, and other solid tumors), with 16 patients per cohort (48 in total, including subjects enrolled from the ILDR-01 study). Eligible participants includes patients with advanced metastatic solid tumors progressing after monotherapy or combination ICB treatment, meeting criteria of ECOG performance status 0-2, life expectancy ≥3 months, and have at least one measurable lesion. Exclusion criteria encompasses prior pelvic radiotherapy, ongoing infections, major organ dysfunction, or concurrent antitumor therapies.

The primary endpoints includes objective response rate (ORR), disease control rate (DCR), progression-free survival after ILDR (PFS2), and the incidence of abscopal effects. Secondary endpoints includes overall survival (OS), treatment safety, α/β diversity changes in gut microbiota, peripheral blood immune cell subset dynamics, and tumor immune microenvironment remodeling characteristics. All patients receives a 1 Gy jejunoileal radiotherapy followed by PD-1/PD-L1 monoclonal antibody administration (in accordance to prior protocols or guidelines) within 24 hours, with maintenance therapy up to 2 years. Therapeutic efficacy is assessed via RECIST v1.1, while therapeutic toxicity is assessed according to CTCAE v5.0.

Paired pre- and post-treatment samples (including wumor tissue, stool, peripheral blood etc.) are collected for metagenomic sequencing, metabolomic analysis, and multi-omics integrative modeling to systematically elucidate the regulation mechanism of gut microbiota-metabolite-immune axis mediated by ILDR. This approach aims to provide theoretical foundations for optimizing treatment strategies in immunotherapy-resistant tumors and identify biomarkers that potentially associated with therapeutic efficacy.

03

Conditions studied

  • Radiotherapy
  • Metastatic Solid Cancers
  • Immune Checkpoint Blockade
  • Esophageal Neoplasms Malignant
  • Lung Neoplasm Malignant
  • Drug Resistance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years, ≤80 years, regardless of gender.
  • level 0-2.
  • Expected life span>3 months.
  • At least one accessible and should be selected as the target lesion for observation according to criteria.
  • Patients with solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression.
  • Patients should not be considered eligible for surgical treatment.
  • Patients with that are assessed as clinically stable after treatment through repeated CT and/or MRI scans are eligible.
  • Patients have complete clinical and pathological information.
  • Patients should not be borthered by any psychological, family, social or geographical conditions that may hinder compliance with the research protocol.
  • Patients should be able to understand the form, voluntarily participate, and sign the informed consent form.
  • Other indicators accord with the general inclusion criteria for clinical trials.

Exclusion criteria

Exclusion Criteria:

  • Patients with to radiation therapy and immunotherapy.
  • Previous occurrence of unacceptable immune related toxic side effects (immune myocarditis, pneumonia, etc.).
  • Patients who were assessed as hyperprogressive disease (HPD).
  • Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment.
  • The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss).
  • Patients with active uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.
  • Significant liver or kidney dysfunction (i.e., laboratory values >3 times the ).
  • Active , , , or syphilis.
  • Brain disorders, symptomatic central nervous system (CNS) or meningeal , or impaired cognitive function.
  • to any drug included in the trial.
  • Drug and/or alcohol abuse.
  • Pregnant or breastfeeding women.
  • Concurrent participation in another therapeutic clinical trial.
  • Poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within ≤14 days after intervention).
  • Major surgery within 30 days.
  • Use of antibiotics, antifungals, antivirals, antiparasitics, or probiotics within 4 weeks before enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Lung cancer arm

    This arm includes patients with metastatic non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) who have progressed after previous immune checkpoint blockades (ICBs) administration, and the intervention involves 1Gy/1F ILDR plus PD-1/PD-L1 inhibitors.

    Radiation: Low-dose radiotherapy to the intestine (ILDR) · Drug: PD-1/PD-L1 monoclonal antibodies

  • Experimental
    Esophageal cancer group

    This arm includes patients with metastatic esophageal cancer (including squamous cell carcinoma or adenocarcinoma) who have progressed after previous ICB administration, and the intervention involves 1Gy/1F ILDR plus PD-1/PD-L1 inhibitors.

    Radiation: Low-dose radiotherapy to the intestine (ILDR) · Drug: PD-1/PD-L1 monoclonal antibodies

  • Experimental
    Other solid tumor group

    This arm includes patients with other malignant solid tumors except lung cancer and esophageal cancer who have progressed after previous ICB administration, and the intervention involves 1Gy/1F ILDR plus PD-1/PD-L1 inhibitors.

    Radiation: Low-dose radiotherapy to the intestine (ILDR) · Drug: PD-1/PD-L1 monoclonal antibodies

Interventions

  • RadiationLow-dose radiotherapy to the intestine (ILDR)

    A single total dose of 1 Gy irradiation targeting the jejunum and ileum. Primary tumor or metastatic lesions that are within the irradiation field are irradiated concurrently.

  • DrugPD-1/PD-L1 monoclonal antibodies

    Pre-progression immunotherapy regimen continues or switches to an alternative PD-1/PD-L1 monoclonal antibody according to clinical guidelines.PD-1/PD-L1 monoclonal antibody will be given 1 day after ILDR at a 3-week interval.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients achieving complete response (CR) or partial response (PR) (sustained ≥4 weeks) per RECIST v1.1.

    Time frame: 6, 12, 24 weeks after ILDR initiation.

  2. Disease Control Rate(DCR)

    Proportion of patients with CR, PR, or stable disease (SD) per RECIST v1.1.

    Time frame: 6, 12, 24 weeks after ILDR initiation.

  3. Progression Free Survival while Receiving ILDR combined Therapy (PFS2)

    Time from ILDR treatment to second documented disease progression (assessed by investigator via PSA, imaging, symptom, or the combinations) or death from any cause.

    Time frame: 6, 12, 24 weeks after ILDR initiation.

  4. Incidence of Abscopal Effect

    Proportion of patients demonstrating tumor response in one or more non-irradiated lesions.

    Time frame: 6, 12, 24 weeks after ILDR initiation.

Secondary outcomes

  1. Overall Survival (OS)

    Time from ILDR treatment initiation to death from any cause.

    Time frame: 24, 48 weeks after radiotherapy initiation.

  2. Cancer-Specific Survival (CSS)

    Time from ILDR treatment initiation to death due to cancer.

    Time frame: 24, 48 weeks after radiotherapy initiation.

  3. Adverse Events

    Proportion of patients with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: 12, 24, 48 weeks after radiotherapy initiation

Other outcomes

  1. Peripheral Blood Analyses

    Peripheral blood analysis includes immune profiling, transcriptomics, immune receptor repertoire, metabolomics, and cytokine analysis

    Time frame: Before the first ILDR, 3-7 days after ILDR initiation, before each subsequent administration of the PD-1/PD-L1 blockade.

  2. Tissue Analyses

    Tissue analyses includes transcriptomics, immune receptor repertoire, and immunohistochemistry.

    Time frame: Before the first ILDR, 3 weeks after the last ILDR or before the next PD-1/PD-L1 blockade administration.

  3. Fecal Analyses

    Fecal analyses include fecal metagenomics and fecal metabolomics.

    Time frame: Before the first ILDR, 3-7 days after each ILDR, after each subsequent PD-1/PD-L1 blockade administration.

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital, Shantou University Medical College
    Shantou, Guangdong 515031, China
    Recruiting
    • Chuangzhen Chen · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jan 2028, 27 months after the start.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 27 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 17, 2025
StartActual
Sep 26, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071103
Lead sponsor
Chuangzhen Chen
Responsible party
Chuangzhen Chen (Director, Shantou University Medical College) — Sponsor-investigator
First posted
Jul 17, 2025
Start date
Sep 26, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 20, 2025

Study contacts

Chuangzhen Chen, MD
Contact
czchen2@stu.edu.cn
+86 13923995569

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion